Neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), and Parkinson’s disease (PD), are becoming an increasing public health concern as the global population ages. Effective treatment options for these debilitating and fatal conditions are severely limited. Although there has been much progress in recent years unraveling disease mechanisms, the underlying causes of these diseases are not well understood. Even in cases where disease-causing mutations have been identified, it is still unclear how they lead to neuronal death, and ultimately, to the specific cognitive and/or motor deficits associated with each disorder.
Migraine, headache disorders and chronic pain are additional areas of unmet need. An estimated 1.5 billion people globally suffer from chronic pain, and in one in three people the ability to sustain an independent lifestyle is impaired due to pain. Furthermore, about 100 million people in the United States suffer from headaches, of which 37 million have migraines. Migraine sufferers typically suffer from moderate to severe pain limiting their participation in normal activities and impacting their overall quality of life. Effective treatments without deleterious side effects are urgently needed.
The key to discovering effective treatments lies in understanding the basic mechanism or pathophysiology of the condition, thus uncovering new pathways and targets. Successful proposals for this Challenge should focus on novel intracellular or extracellular targets that can be modulated by small molecules or biologics to alleviate the conditions of people suffering from neurodegenerative disorders, including ALS, HD and PD, as well as migraine, headache disorders, or pain.
This is an electronic Request-for-Partners (eRFP) Challenge. The Solver will write a proposal (maximum of 10 pages, not including references and contact details) to be evaluated by Teva.
The ALS Association and the Huntington’s Disease Society of America (HDSA) are partnering with Teva and co-sponsoring the Challenge awards to seek novel targets with therapeutic potential for ALS and HD, respectively.
The top submissions will be considered for awards ranging from $10,000 to $30,000. Up to $40,000 in cash awards may be distributed. Solvers are NOT eligible for multiple awards. The award has no strings attached; Teva does not request ownership of intellectual property. In addition, if there is mutual interest of the parties, Teva may invite selected Solvers to work out terms for a collaboration contract to further investigate the target. The monetary value of the contract will vary depending on the amount of work to be delivered and the agreed time frame.